glp 1 receptor agonist contraindications for switching Table 5 from Glucagon-Like Peptide-1

To address the problem of once-a-day injections of Liraglutide, Lilly launched Dulaglutide, which is administered once a week and was approved by the FDA in 2014 for the treatment of type 2 diabetes

However, stopping these medications often leads to regaining weight because they do not permanently change the bodys weight regulation

In November 2025 Novo Nordisk filed for submission to the FDA for a higher dose of semaglutide, 7.2mg

doi: 10.1210/en.2018-00004 42 WeiLMoWLanSet al

GLP-1 also slows down the rate at which the stomach empties, which helps control appetite and food intake

Balance diagnostics for comparing the distribution of baseline covariates between treatment groups in propensity-score matched samples